
Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials.

Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials.

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.

Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.

Prenatal exposure to air pollution was associated with childhood obesity risk in a recent study, highlighting the urgent need for environmental health awareness.

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.

The Trump administration's policies reshape global health dynamics, presenting Europe with both challenges and opportunities for leadership in health governance.

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic kidney disease.

Air pollution exposure, both before and after birth, significantly escalates the risk of respiratory infections in children.

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

Significant demographic differences were found when evaluating the use of depression services in people living with HIV and depression.

Findings underscore the potential limitations of using systemic inflammatory indices like the Dietary Inflammatory Index and Systemic Immune-Inflammation Index to assess organ-specific conditions.

The recent decision in Kennedy v Braidwood could give Robert F. Kennedy Jr, secretary of HHS, the ability to remove all members of the US Preventive Services Task Force (USPSTF) if desired, according to Jeffrey Fitzgerald, JD.

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more targeted public health efforts.

A webinar held by KFF on July 9 emphasized the immediate effects of the new budget bill, highlighting the impacts on Medicaid and health spending in the next decade.

Families caring for individuals with Duchenne muscular dystrophy (DMD) face significant financial burdens from necessary home and vehicle modifications to enhance quality of life.

Prenatal and early-life factors significantly influence childhood obesity trajectories, highlighting the need for early interventions to promote healthy growth.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

A new survey reveals that 80% of Americans not enrolled in Medicare are afraid that Medicare will not be there when they are eligible to enroll.

The FDA's new guidance shapes drug development for myelodysplastic syndromes (MDS), emphasizing trial design, patient selection, and safety reporting for better treatment outcomes.

The global burden of pulmonary arterial hypertension (PAH) remains great, with cases jumping 85.6% in 32 years.

Many patients value conversations with their rheumatologists and oncologists more than just reading information from a website.

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.


Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
